No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
pubmed:
23
7
2020
medline:
20
2
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
Most studies about HIV-1 molecular evolution have shown the lack of viral evolution on effective antiretroviral therapy (ART), although controversial results have been documented. We therefore aimed to look for evidence of HIV-1 evolution in patients who initiated ART at the time of primary HIV-1 infection (PHI). We included retrospectively 20 patients diagnosed at PHI, treated at the time of acute infection and with subsequent effective long-term suppressive ART (HIV viral load <20 copies/ml during at least 5 years without any blips). Longitudinal blood samples were deep sequenced using Illumina Miseq. Drug-resistance-associated mutations were retained at 2% cutoff and interpreted using the latest Agence Nationale de Recherches sur le Sida et les Hépatites Virales resistance algorithm. Viral evolution was established when temporal structure on maximum-likelihood phylogenetic tree and significant change over time of HIV-1 genetic diversity measured as the average pairwise distance was observed. Emergences or disappearances of drug-resistance-associated mutations were detected in the blood cells during follow-up despite sustained virological control. In all patients, tree topologies showed an absence of segregation between sequences and blood viral populations from all time-points were intermingled. Comparison of the average pairwise distance showed the absence of significant viral diversity at the time of primary infection and afterwards during 5 years of full virological control under ART. Despite a slight variation of minority resistance-associated mutation variants, there was no clear evidence of viral evolution during a prolonged period of time in this population of highly controlled adult patients treated at time of PHI.
Identifiants
pubmed: 32694418
doi: 10.1097/QAD.0000000000002629
pii: 00002030-202010010-00005
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1745-1753Commentaires et corrections
Type : CommentIn
Références
Kassutto S, Rosenberg ES. Primary HIV type 1 Infection. Clin Infect Dis 2004; 38:14471453.
Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009; 23:1987.
Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:18711879.
Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, Blanc C, et al. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One 2013; 8:e64219.
Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:14101418.
Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013; 68:11691178.
Schmid A, Gianella S, von Wyl V, Metzner KJ, Scherrer AU, Niederöst B, et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One 2010; 5:e13310.
Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One 2012; 7:e43754.
Grijsen ML, Steingrover R, Wit FWNM, Jurriaans S, Verbon A, Brinkman K, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med 2012; 9:e1001196.
Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, et al. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. AIDS 2016; 30:879888.
Fidler S, Olson AD, Bucher HC, Fox J, Thornhill J, Morrison C, et al. Virological blips and predictors of post treatment viral control after stopping ART started in primary HIV infection. J Acquir Immune Defic Syndr 2017; 74:126133.
Chaillon A, Gianella S, Lada SM, Perez-Santiago J, Jordan P, Ignacio C, et al. Size, composition, and evolution of HIV DNA populations during early antiretroviral therapy and intensification with maraviroc. J Virol 2018; 92: doi:10.1128/JVI.01589-17.
doi: 10.1128/JVI.01589-17
Lorenzo-Redondo R, Fryer HR, Bedford T, Kim E-Y, Archer J, Pond SLK, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 2016; 530:5156.
van Zyl G, Bale MJ, Kearney MF. HIV evolution and diversity in ART-treated patients. Retrovirology 2018; 15:14.
Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O'Shea A, et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog 2014; 10:e1004010.
Avettand-Fènoël V, Chaix M-L, Blanche S, Burgard M, Floch C, Toure K, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009; 81:217223.
Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, et al. Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 2012; 28:16471649.
Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 1993; 10:512526.
Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, et al. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. J Antimicrob Chemother 2015; 70:21082120.
Chéret A, Durier C, Mélard A, Ploquin M, Heitzmann J, Lécuroux C, et al. Impact of early cART on HIV blood and semen compartments at the time of primary infection. PLoS One 2017; 12:e0180191.
Leite TF, Delatorre E, Côrtes FH, Ferreira ACG, Cardoso SW, Grinsztejn B, et al. Reduction of HIV-1 reservoir size and diversity after 1 year of cART among Brazilian individuals starting treatment during early stages of acute infection. Front Microbiol 2019; 10:145.
Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K, et al. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS 2008; 22:24412450.
Visseaux B, Assoumou L, Mahjoub N, Grude M, Trabaud M-A, Raymond S, et al. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?. J Antimicrob Chemother 2020; 75:183193.
Gantner P, Morand-Joubert L, Sueur C, Raffi F, Fagard C, Lascoux-Combe C, et al. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. J Antimicrob Chemother 2016; 71:751761.
Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:38793884.
Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54:724732.
Fourati S, Lambert-Niclot S, Soulie C, Wirden M, Malet I, Valantin MA, et al. Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments. AIDS 2014; 28:487491.
Van Zyl GU, Katusiime MG, Wiegand A, McManus WR, Bale MJ, Halvas EK, et al. No evidence of HIV replication in children on antiretroviral therapy. J Clin Invest 2017; 127:38273834.
Kearney MF, Wiegand A, Shao W, McManus WR, Bale MJ, Luke B, et al. Ongoing HIV replication during ART reconsidered. Open Forum Infect Dis 2017; 4:ofx173.
Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, Lederman M, et al. Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy. J Virol 2016; 90:13691376.
Achaz G, Palmer S, Kearney M, Maldarelli F, Mellors JW, Coffin JM, et al. A robust measure of HIV-1 population turnover within chronically infected individuals. Mol Biol Evol 2004; 21:19021912.